Strategic Divestments: Maximising Product Lifecycle Value
Published Oct 21, 2024
Published 24th September 2024
Navigating the pharmaceutical landscape in the European Union (EU) can be a complex and daunting task, particularly for small and medium-sized enterprises (SMEs). Accreditation with the European Medicines Agency (EMA) is a crucial step for SMEs aiming to bring orphan drugs or innovative medical products to the market. SME accreditation can offer additional benefits to the companies that have orphan designation (OD), when combined, these two frameworks can offer significant advantages to the sponsors. This blog provides an overview of the benefits of EMA SME accreditation for orphan drug and other medicinal product developers, and how the upcoming reforms in EU pharmaceutical legislation impact SMEs, and the incentives and services available to support these businesses.
The EMA offers a variety of incentives designed to support SMEs in their journey to bring new medicines to market:
Financial Incentives of SME holders:
MA: marketing authorisation; MAA: marketing authorisation application; OD: orphan designation
The EU pharmaceutical legislation is continuously evolving to enhance the regulatory environment, ensuring that it keeps pace with scientific advancements and the needs of patients. Recent reforms have significant implications for SMEs:
At DLRC, we provide comprehensive support to SMEs navigating EMA accreditation.
If you are a non-EEA-based SME company, through our German affiliate Orphix Consulting GmbH’s SME holding services, you can benefit from all the SME incentives in the EU.
We offer expert advice on your SME application, helping you understand and comply with EMA requirements. Our team of experienced professionals ensures that the submission is meticulously prepared, and any further enquiries from the EMA are handled with care. We have helped numerous clients to attain SME accreditation.
Our experts are dedicated to assisting you with SME renewal each year to ensure your SME status is active so that you continue to qualify for incentives.
We also provide transfer services for SMEs from different organisations or different affiliates within the same organisation.
European Medicines Agency (EMA) accreditation is a critical step for small and medium-sized enterprises (SMEs) aiming to bring rare or orphan drugs and innovative medical products to the European market. Understanding the implications of recent European Union (EU) pharmaceutical legislation reforms and leveraging the available incentives can significantly enhance an SMEs chance of success. With our specialised services, we are committed to guiding SMEs through the complex regulatory landscape, ensuring they can focus on what they do best: developing groundbreaking medical solutions.
For more information on how we can support your SME in achieving EMA accreditation, please contact us today at hello@dlrcgroup.com with any questions you may have – our experienced team of SME experts are here to assist you in the advancement of your SME accreditation and will participate in these discussions with you to facilitate your communication with the regulatory agencies.
Published Oct 21, 2024
Published Oct 18, 2024
Published Oct 10, 2024
Published Oct 07, 2024
Published Sep 26, 2024
Published Sep 24, 2024
Published Sep 10, 2024
Published Aug 30, 2024
Published Aug 19, 2024